All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Paris and Boston, June 4, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 4, 2026, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. With a quorum of 45.79%, all resolutions recommended by the Board of Directors were adopted, with the exception of the 15th. These notably included:
– the approval of the statutory and consolidated financial statements for the financial year ended December 31, 2025, and the allocation of earnings;
– the renewal and appointment of members of the Board of Directors — particularly the appointment of Ms. Elsy Boglioli Hofman as a new director, as well as those of Mr. Richard Di Benedetto and Mr. Randall Stanicky, replacing Ms. Claire Biot and Ms. Jacquelien ten Dam respectively, whose terms of office had expired;
– all financial delegations granted to the Board of Directors.
The 15th resolution — a delegation to issue securities with cancellation of preferential subscription rights in the context of an equity or bond financing line — received 66.37% of the votes, below the two-thirds majority required for extraordinary resolutions and was therefore not adopted.
The 23rd resolution, relating to a capital increase reserved for members of a company savings plan, which the Board of Directors had recommended voting against, was not adopted.
Details on the vote results are available on the Company’s website.
